Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.
Abstract: Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) ?-polyglutamic acid (?-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the ?-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising ?-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient.
Type:
Grant
Filed:
June 16, 2013
Date of Patent:
October 4, 2016
Assignee:
NATIONAL HEALTH RESEARCH INSTITUTES
Inventors:
Yu-Chun Chen, Wen-Yu Su, Yen-Hsien Lee, Ko-Hua Chen, Feng-Huei Lin
Abstract: The present disclosure is to destroy adipose tissue non-invasively by using focused ultrasound (FUS) and to increase the treatment efficiency by the synergy of the novel FUS and electrical stimulation. Lipid can be released from the destroyed adipocytes and stay in the interstitial fluid of undestroyed adipocytes. In the meanwhile or after the treatment of FUS, a passive exercise of muscle in thighs or other parts is performed by electrical stimulation to consume energy. Therefore, metabolism of the free lipid can be enhanced by supplying energy to the muscles. The ultrasound treatment of the present disclosure is able to increase the treatment area, and while in combination with electrical stimulation, it can efficiently remove lipids in the circulation.
Type:
Grant
Filed:
October 11, 2013
Date of Patent:
September 6, 2016
Assignees:
National Health Research Institutes, National Cheng Kung University
Abstract: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.
Abstract: Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
July 12, 2016
Assignees:
National Health Research Institutes, Molecular Targeting Technologies, Inc.
Abstract: The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.
Type:
Grant
Filed:
December 27, 2013
Date of Patent:
July 5, 2016
Assignees:
Development Center for Biotechnology, National Health Research Institutes
Abstract: A TEM specimen kit is disclosed, which comprises: (a) a top substrate and a bottom substrate, the top and the bottom substrates being transparent and substantially parallel to each other; (b) a first spacer and a second spacer, located beneath the top substrate and sitting on the bottom substrate, the second spacer being opposite to and spaced apart from the first spacer at a distance of d; and (c) a chamber formed between the top and bottom substrate and between the first and second spacer, the chamber having two ends open to the atmosphere and characterized by having a height defined by the thickness h of the spacer, wherein the height being smaller than the diameter of a red blood cell. Also enclosed are methods for preparing a dry specimen for TEM nanoparticle characterization, and methods for analyzing TEM images of nanoparticles in a liquid sample.
Type:
Grant
Filed:
July 8, 2013
Date of Patent:
July 5, 2016
Assignees:
NATIONAL HEALTH RESEARCH INSTITUTES, MATERIALS ANALYSIS TECHNOLOGY (US) CORP.
Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.
Type:
Application
Filed:
December 31, 2014
Publication date:
June 30, 2016
Applicants:
Development Center for Biotechnology, DCB-USA LLC, National Health Research Institutes
Abstract: CpG-oligodeoxynucleotides (CpG-ODN), as potent immune stimuli developed for using as adjuvant in different species, are disclosed herein. TLR9 is the cellular receptor for CpG-ODN, and current developed CpG-ODN has low activity to rabbit TLR9. Here, a type of CpG-ODN containing a GACGTT or AACGTT motif in about 11-14 deoxynucleotides was demonstrated to have potent immunostimulatory activity to rabbit TLR9, and capable of boosting a less toxic and potent antibody response in rabbits.
Abstract: This disclosure includes the identification of molecular markers, including ASPM, ATP9A, ACOX3, CD-C45L, SLC40A1, AGR2, and those found in TABLE 2, that are associated with the differentiation and the clinical prognosis of pancreatic cancer. More specifically, the disclosure includes the identification of sets of gene markers whose expression levels can be used to distinguish pancreatic cancers with higher degrees of differentiation from those with lower degrees of differentiation. These markers can be used to predict clinical prognosis of pancreatic cancer, including disease progression, recurrence or death of the hosts. The disclosure also provides methods of treating glandular cancers and kits for assaying glandular cancers, such as pancreatic cancer, breast cancer, and prostate cancer, by inhibiting the expression of ASPM or its ability to activate or maintain the Wnt signaling activity and/or the cancer stem cell populations of said glandular cancers.
Abstract: The invention provides an isolated antigen polypeptide that can be expressed in a subject with ovarian cancer. Also provided is the diagnosis of ovarian cancer by using the antigen polypeptide of the invention and the prevention and/or treatment of ovarian cancer by suppressing the gene of the antigen polypeptide of the invention.
Type:
Grant
Filed:
March 9, 2011
Date of Patent:
December 1, 2015
Assignees:
TAIPEI MEDICAL UNIVERSITY, NATIONAL HEALTH RESEARCH INSTITUTE
Abstract: A method for in vitro detection of the presence of a C-terminal truncation mutation of a hepatitis B virus (HBV) surface (S) gene encoding a small S protein in an isolated nucleic acid sample is disclosed. An in vitro diagnostic kit for use in the aforementioned method is also disclosed.
Abstract: The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided.
Type:
Grant
Filed:
July 20, 2009
Date of Patent:
August 4, 2015
Assignee:
National Health Research Institutes
Inventors:
Yen-Hung Chow, Hsiao-Yun Shao, Charles Sia, Pele Chong
Abstract: A caged platinum nanocluster complex is disclosed. The complex comprises (a) an amine-terminated dendrimer; and (b) a platinum nanocluster comprising platinum oxides, the platinum nanocluster being confined inside of the amine-terminated dendrimer. The complex exhibits cytotoxicity to cancer cells. A double-caged platinum nanocluster complex is also disclosed, which comprises polyethylene glycol (PEG) coated on the surface of a dendrimer caged platinum nanocluster complex. The double-caged caged platinum nanocluster complex comprises pH-sensitive bonds on the surface thereof. Also disclosed are methods of preparing and using the same.
Abstract: The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.
Type:
Application
Filed:
December 27, 2013
Publication date:
July 2, 2015
Applicants:
NATIONAL HEALTH RESEARCH INSTITUTES, DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Abstract: Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.
Abstract: Fused multicyclic compounds of formula (I): wherein R?, R?, X, Y, Z, A, B, C, D, and n are defined herein. Also disclosed are a method for inhibiting protein kinase (e.g., Aurora kinase) activity and a method for treating a protein kinase mediated disorder (e.g., cancer) with these compounds.
Abstract: A specimen kit having a tiny chamber is disclosed for a specimen preparation for TEM. The space height of the chamber is far smaller than dimensions of blood cells and therefore is adapted to sort nanoparticles from the blood cells. The specimen prepared under this invention is suitable for TEM observation over a true distribution status of nanoparticles in blood. The extremely tiny space height in Z direction eliminates the possibility of aggregation of the nanoparticles and/or agglomeration in Z direction during drying; therefore, a specimen prepared under this invention is suitable for TEM observation over the dispersion and/or agglomeration of nanoparticles in a blood.
Type:
Grant
Filed:
July 9, 2012
Date of Patent:
March 3, 2015
Assignees:
Materials Analysis Technology (US) Corp., National Health Research Institutes
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, and X are defined herein. Also disclosed are pharmaceutical compositions and methods related to use of these compounds.